6.5 C
New York
Friday, December 3, 2021

This FDA-approved drug for hepatitis C reduces antibiotic resistance and increases bacterial sensitivity

Must Read

Study links altered ratio of baby boys to baby girls to pollutants

For years, people have had theories on what determines the shifting ratio of baby boys to baby...

Physicists create and observe a new state of matter, ‘Quantum Spin Liquid’

Harvard physicists have created and observed a new state of matter that has been predicted and pursued...

Astronomers find a featherweight sub-Earth exoplanet as dense as pure iron

'GJ 367 b' is a featherweight among extrasolar planets. The newly discovered planet is one of the...
Kuldeep Singh
Kuldeep is a Journalist and Writer at Revyuh.com. He writes about topics such as Apps, how to, tips and tricks, social network and covers the latest story from the ground. He stands in front of and behind the camera, creates creative product images and much more. Always ready to review new products. Email: kuldeep (at) revyuh (dot) com

A new study led by New York University researchers found that an FDA-approved hepatitis C drug can increase bacterial sensitivity to antibiotics and decrease antibiotic resistance.

In bacteria, the drug telaprevir works by inhibiting the action of chaperones, which are crucial proteins that fold other proteins in the cell.

“Telaprevir is the first previously clinically approved compound that has been shown to inhibit chaperone function in bacteria,” says Tania Lupoli – the study’s senior author.

“Our research marks a vital step in developing small molecule chaperone inhibitors that can be used in bacteria to increase the power of antibiotics and slow down the evolution of antibiotic resistance.”

From single-cell bacteria to humans, chaperones can be found in practically every cell of every organism. Chaperones are the targets of ongoing drug discovery research because of their crucial function in protein folding—and what occurs when proteins misfold, which can lead to cell toxicity—but researchers have struggled to find small molecule that can selectively target or bind to chaperones.

The goal of this work was to find tiny compounds that could switch off the action of chaperones in bacteria that cause disease. They searched nearly 25,000 compounds, including 1,300 licensed drugs, for small molecules that inhibit chaperones in Mycobacterium TB, the germ that causes tuberculosis. 

They discovered telaprevir, an antiviral drug licensed by the FDA for the treatment of hepatitis C. They demonstrated that telaprevir binds to mycobacterial chaperones and inhibits their ability to fold proteins in a series of lab studies using model mycobacteria. This made the mycobacteria more susceptible to drugs, including streptomycin, a routinely used tuberculosis treatment.

Chaperones can also fix the proteins in the cell that induce antibiotic resistance, so blocking chaperone activity with telaprevir reduced mycobacteria susceptibility to the first-line tuberculosis treatment rifampicin. Antibiotic resistance reduction is a key public health goal in the United States and around the world, since an increasing variety of illnesses, including tuberculosis, become more difficult to treat as antibiotics become less effective.

“In the future, we envision that small molecule chaperone inhibitors could be used in combination with antibiotics to enhance antibiotic potency and lower resistance,” says the study author.

While the researchers were extremely happy to discover telaprevir as a chaperone inhibitor, they are still investigating hundreds of telaprevir analogs—compounds with similar molecular structures—to see if others bind more tightly to chaperones, which is essential for moving the research into animal or clinical studies. Future research will also look into how to adapt chaperone inhibitors to just inhibit specific chaperones, such as blocking chaperones in bacteria but not human cells.

“Our work contributes to a small but growing list of small molecules that block the function of chaperones and provides a promising avenue for ongoing study of the role that telaprevir and its analogs can play when administered with antibiotics,” concludes Lupoli.

Source: 10.1016/j.chembiol.2021.11.004

Image Credit: iStock

You were reading: This FDA-approved drug for hepatitis C reduces antibiotic resistance and increases bacterial sensitivity

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -